Using videocapsule endoscopy to detect small bowel cancer in Lynch syndrome patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the incidence of neoplasia and preneoplastic lesions in the small bowel of patients with Lynch syndrome using videocapsule endoscopy (VCE). Lynch syndrome is associated with a significantly increased risk of small bowel cancer due to pathogenic variants in mismatch repair genes. The VCE involves swallowing a capsule with a camera that captures images of the gastrointestinal tract, which are then analyzed to identify potential cancers. This multicentric observational study will collect prospective data without altering the current standard of care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pathogenic germline variant in one of the MMR genes (MLH1, MSH2/Epcam, MSH6, or PMS2).

Exclusion Criteria:

* Patients younger than 18 years of age
* Patients unwilling or unable to provide informed consent
* Patients with prior small bowel surgery
* Patients with a contraindication to VCE

Where it's running

• San Raffaele Scientific Institute, Gastroenterology and Gastrointestinal Endoscopy Unit
  Milan, Lombardy, Italy Recruiting

Study contacts

• Study coordinator: Giulia Martina Cavestro, MD PhD
• Email: cavestro.giuliamartina@hsr.it
• Phone: +390226437217

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Liquid biopsy and machine learning to detect early colorectal cancer, advanced adenomas, Lynch-related cancers, and residual disease

  This project will test a blood-based liquid biopsy that uses microRNA signals and machine learning to detect colorectal cancer, advanced adenomas, Lynch-associated cancers, and molecular residual disease in people who have a colonoscopy.

  Recruiting San Raffaele University · Milan, Lombardy and 3 other locations · NCT07450612

• Understanding the immune response in Lynch syndrome patients

  This study is trying to see if certain antibodies in the immune system can help spot early signs of cancer in people with Lynch syndrome.

  Recruiting at 5 sites San Raffaele University · Monrovia, California and 4 other locations · NCT06708429

• Increasing Genetic Testing for Families at Risk of Cancer

  This study is testing a new way to encourage families at risk of cancer to get genetic testing by having healthcare providers reach out directly to them instead of relying on patients to share their results.

  Recruiting at 8 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT05420064

• Capsule camera screening of the small intestine for people with Lynch syndrome

  This project looks back at past small-bowel capsule endoscopy exams to see if they detect precancerous lesions or early cancer in people with Lynch syndrome.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07472686

• Paclitaxel given inside the abdomen with systemic therapy for GI cancers with peritoneal spread

  This phase II study tests a combination of intraperitoneal and systemic chemotherapy (paclitaxel) in adults with digestive tract cancers that have spread to the peritoneum.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07795749

• Cutting down ultra-processed foods for people at high cancer risk

  This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.

  Recruiting at 2 sites Gustave Roussy, Cancer Campus, Grand Paris · Avignon and 2 other locations · NCT07436312

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.